American Journal of Hematology最新文献

{"title":"Noninvasive Diagnosis of Splenosis Using Tc‐99m Heat‐Denatured Red Blood Cell Scintigraphy","authors":"Natacha Dewarrat, Katharina Auf der Springe, Francesco Grandoni, Rami Hajri, Mathilde Gavillet","doi":"10.1002/ajh.70501","DOIUrl":"https://doi.org/10.1002/ajh.70501","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"375 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148915497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulant Therapy and Bleeding‐Related Hospitalizations in Patients With Cancer: A National Cohort Study","authors":"Amber Afzal, Luo Suhong, Amir Mahmoud, Brian F. Gage, Kristen M. Sanfilippo","doi":"10.1002/ajh.70491","DOIUrl":"https://doi.org/10.1002/ajh.70491","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"11 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148902026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity-Related Inflammation Masks Iron Deficiency in US Women.","authors":"Sixtus Aguree, Sai Chakrri Tadikonda","doi":"10.1002/ajh.70496","DOIUrl":"10.1002/ajh.70496","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148899818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonally Related Chronic Lymphocytic Leukemia and Malignant Histiocytic Neoplasm (Histiocytic Sarcoma With Overlapping Langerhans Cell Phenotype): Divergent Evolution From a Shared Cell‐Of‐Origin","authors":"Adelaide J. Kwon,Lindsay K. Hill,Reiko Tachibana,Estelle Oertling,Lin He,Jeffrey Gagan,Prasad Koduru,Franklin Fuda,Jing Xu,Miguel Cantu,Stephen Chung,Benjamin Kroger,Praveen Ramakrishnan Geethakumari,Weina Chen","doi":"10.1002/ajh.70494","DOIUrl":"https://doi.org/10.1002/ajh.70494","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"9 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma","authors":"Cong Li,&nbsp;Tao Lei,&nbsp;Xiyue Xu,&nbsp;Jialiang Lu,&nbsp;Xiu Zhu,&nbsp;Zhilu Chen,&nbsp;Xiang Weng,&nbsp;Haifeng Yu,&nbsp;Xi Chen,&nbsp;Shuailing Peng,&nbsp;Shuiyun Han,&nbsp;Haiyan Yang","doi":"10.1002/ajh.70366","DOIUrl":"10.1002/ajh.70366","url":null,"abstract":"<p>Relapsed/refractory (r/r) angioimmunoblastic T-cell lymphoma (AITL) is associated with a dismal prognosis, with historical overall survival (OS) &lt; 6 months, underscoring the urgent need for novel therapies. We conducted the RCLARITY trial to evaluate the efficacy and safety of a chemotherapy-free regimen in this patient population. This single-arm, multicenter, prospective Phase II trial enrolled adult patients with r/r AITL. Patients received rituximab (375 mg/m² intravenously on Day 1), lenalidomide (15 mg orally on Days 1–21), and chidamide (30 mg orally twice weekly) in 28-day cycles for up to 6 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints included the overall response rate (ORR), OS, duration of response (DoR), and safety. In total, 28 patients were enrolled between August 2019 and June 2024. The median age was 64 years (range, 44–70), and 71.4% had refractory disease. The ORR was 71.4% (complete remission: 32.1%), median PFS was 5.5 months (95% confidence interval [CI], 3.5–7.6), median OS was 17.6 months (95% CI, 10.3–24.8), and median DoR among responders was 10.7 months (95% CI, 2.7–16.0). Notably, 50% of patients with clonal Ig heavy- or light-chain rearrangements achieved PFS &gt; 16 months. All nine patients with baseline serum EBV-DNA positivity converted to undetectable levels after two cycles. No Grade 5 adverse events or venous thromboembolic events occurred. The most common hematological adverse events per cycle were leukopenia (14.3%), thrombocytopenia (12.4%), and neutropenia (11.4%). Overall, the RLC regimen induced clinically meaningful anti-tumor activity with manageable toxicity in patients with r/r AITL.</p><p>\u0000 <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT04319601.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 S3","pages":"18-26"},"PeriodicalIF":9.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147925659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib-Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET-CT","authors":"Lixia Sheng,&nbsp;Huijie Hu,&nbsp;Yanli Lai,&nbsp;Shuyan Wang,&nbsp;Di Wang,&nbsp;Shanhao Tang,&nbsp;Kaihong Xu,&nbsp;Yongcheng Sun,&nbsp;Ping Zhang,&nbsp;Binbin Lai,&nbsp;Li Hu,&nbsp;Lieguang Chen,&nbsp;Yuning Pan,&nbsp;Sheng Nie,&nbsp;Xiang Gao,&nbsp;Lei Fan,&nbsp;Guifang Ouyang","doi":"10.1002/ajh.70402","DOIUrl":"10.1002/ajh.70402","url":null,"abstract":"<p>This prospective biomarker study evaluated serial CSF ctDNA monitoring in newly diagnosed PCNSL treated with R-MO induction therapy. Mid-treatment ctDNA clearance was significantly associated with complete response and superior progression-free survival, showing stronger predictive value than interim PET-CT in this cohort. These findings support CSF ctDNA clearance as a promising molecular biomarker for early response assessment in PCNSL.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 S3","pages":"85-90"},"PeriodicalIF":9.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148210073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study","authors":"Meng Wu,&nbsp;Mingxing Zhong,&nbsp;Hongmei Jing,&nbsp;Caixia Li,&nbsp;Yuerong Shuang,&nbsp;Zengjun Li,&nbsp;Sujun Gao,&nbsp;Jun Luo,&nbsp;Jian Zhou,&nbsp;Jie Ji,&nbsp;Wenrong Huang,&nbsp;Xiaopei Wang,&nbsp;Yuqin Song,&nbsp;Jun Zhu,&nbsp;Hui Liu,&nbsp;Yao Liu,&nbsp;Weiping Liu","doi":"10.1002/ajh.70409","DOIUrl":"10.1002/ajh.70409","url":null,"abstract":"&lt;p&gt;High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) has become the standard treatment for relapsed or refractory lymphomas and newly diagnosed high-risk lymphoma [&lt;span&gt;1, 2&lt;/span&gt;]. Successful auto-HSCT relies on the effective mobilization and collection of an adequate number of CD34&lt;sup&gt;+&lt;/sup&gt; hematopoietic stem cells (HSCs) [&lt;span&gt;3&lt;/span&gt;], with a minimum required dose of ≥ 2 × 10&lt;sup&gt;6&lt;/sup&gt; CD34&lt;sup&gt;+&lt;/sup&gt; cells/kg and an optimal target of ≥ 5 × 10&lt;sup&gt;6&lt;/sup&gt; CD34&lt;sup&gt;+&lt;/sup&gt; cells/kg [&lt;span&gt;4&lt;/span&gt;]. Plerixafor, a novel CXCR4 antagonist, exerts potent synergistic effects on HSC mobilization when combined with granulocyte colony-stimulating factor (G-CSF) [&lt;span&gt;5&lt;/span&gt;]. Several large-scale randomized clinical trials have shown that administering plerixafor after 4 days of G-CSF significantly increases the number of peripheral CD34&lt;sup&gt;+&lt;/sup&gt; cells, reduces the number of days of apheresis required, and improves mobilization success rates, with a favorable safety profile [&lt;span&gt;6-8&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Although standard mobilization regimens, such as chemotherapy-based or steady-state mobilization, have been established [&lt;span&gt;4&lt;/span&gt;], up to 40% of patients still experience mobilization failure [&lt;span&gt;9-11&lt;/span&gt;]. These patients often face risks such as prolonged treatment duration, accelerated disease progression, increased treatment burden, and substantial healthcare system costs [&lt;span&gt;8&lt;/span&gt;]. Several small-scale studies have suggested that plerixafor plus G-CSF may be a promising option for this special patient population [&lt;span&gt;12-18&lt;/span&gt;]; however, most of these studies were small-scale retrospective or prospective investigations conducted in Europe and the United States, and enrolled heterogeneous populations that included both lymphoma and multiple myeloma patients, rather than focusing exclusively on lymphoma [&lt;span&gt;12-18&lt;/span&gt;]. In the absence of large-scale studies, no consensus exists regarding the optimal mobilization approach.&lt;/p&gt;&lt;p&gt;We conducted this investigator-initiated, open-label, multicenter, single-arm study across 36 centers in China to further evaluate the safety and efficacy of plerixafor plus G-CSF in mobilizing CD34&lt;sup&gt;+&lt;/sup&gt; HSCs in poor mobilizers (PMs). This study has been registered with ClinicalTrials.gov (NCT05510544). Eligible patients were aged 18–70 years, had pathologically confirmed lymphoma, and were candidates for auto-HSCT. Patients were enrolled after meeting at least one predefined poor mobilization criteria during the current mobilization/collection course: (1) poor steady-state mobilization: G-CSFwas initiated after at least 3 weeks post-chemotherapy, and peripheral blood CD34&lt;sup&gt;+&lt;/sup&gt; cells &lt; 10/μL on day 4 of G-CSF treatment; (2) poor chemotherapy mobilization: G-CSF was initiated at the nadir of white blood cell (WBC) count post-chemotherapy, and peripheral blood CD34&lt;sup&gt;+&lt;/sup&gt; cells was &lt; 10/μL when the WBC count recovered ","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 S3","pages":"79-84"},"PeriodicalIF":9.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70409","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148336026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell Lymphoma","authors":"Shenrui Bai,&nbsp;Yongping Song,&nbsp;Liang Wang,&nbsp;Fang Liu,&nbsp;Yexiong Li,&nbsp;Shunan Qi,&nbsp;Zhigang Peng,&nbsp;Ying Zhao,&nbsp;Huiqiang Huang,&nbsp;Yi Xia,&nbsp;Bing Bai,&nbsp;Xiaojie Fang,&nbsp;Man Nie,&nbsp;Jun Cai,&nbsp;Yi Cao,&nbsp;Xinna Gao,&nbsp;Qihua Zou,&nbsp;Qingqing Cai,&nbsp;Yuchen Zhang","doi":"10.1002/ajh.70387","DOIUrl":"10.1002/ajh.70387","url":null,"abstract":"&lt;p&gt;Natural killer/T-cell lymphoma (NKTCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL), and predominantly occurs in East Asia and Latin America [&lt;span&gt;1, 2&lt;/span&gt;]. NKTCL is closely associated with Epstein–Barr virus (EBV) infection, contributing to a notable pathological feature of the upregulation of programmed death-ligand 1 (PD-L1) on tumor cells [&lt;span&gt;3&lt;/span&gt;], which provides a mechanistic rationale for immune checkpoint blockade in NKTCL. Immune checkpoint inhibitors (ICIs) have shown promising activity and mild toxicities in both relapsed/refractory and frontline settings and are now widely incorporated into routine clinical practice [&lt;span&gt;4-7&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Despite the expanding use of ICIs, a substantial proportion of patients exhibit treatment resistance or experience relapse after an initial response. Real-world evidence defining subsequent treatment approaches and associated clinical outcomes following immunotherapy failure remains limited. In light of these observations, we conducted a multicenter retrospective study to analyze the clinical characteristics, treatment patterns, and outcomes of patients with NKTCL who experienced treatment failure after ICI-based therapy. Our aim was to evaluate the efficacy of different salvage treatment strategies, analyze post-immunotherapy survival outcomes, and identify critical prognostic factors in this group of patients.&lt;/p&gt;&lt;p&gt;This analysis included patients diagnosed with NKTCL between October 2015 and October 2024 at six hospitals in China. Eligible patients had received ICI-based therapies and subsequently developed refractory disease, relapsed after an initial response, or discontinued immunotherapy due to intolerable toxicity. This study was approved by the institutional review boards of each participating center and was conducted in compliance with the Declaration of Helsinki.&lt;/p&gt;&lt;p&gt;The post-immunotherapy overall survival (OS-2) was defined as the time from immunotherapy cessation to death from any cause. The post-immunotherapy progression-free survival (PFS-2) was defined as the time from immunotherapy cessation to the first subsequent treatment progression or death. OS-1 was defined as the time from initiation of immunotherapy to death from any cause. PFS-1 was defined as the time from initiation of immunotherapy to progression or death (Figure S1). Responses to the ICI-based regimen and the first post-immunotherapy salvage treatments were determined by the treating physicians in accordance with the 2014 Lugano criteria [&lt;span&gt;8&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;A workflow of the study is shown in Figure 1A. Among 821 screened patients, 186 met inclusion criteria. The baseline characteristics before immunotherapy are summarized in Table S1. The median number of prior treatment lines before immunotherapy was one (range, 0–7). The baseline characteristics following the failure of the ICI-based treatment are summarized in Table 1. The median age was 43 years (interquartile range [IQR], 32–54), a","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 S3","pages":"72-78"},"PeriodicalIF":9.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutation Profiling, Efficacy Monitoring, and Prognosis Evaluation Using Circulating Tumor DNA in Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Observational Study","authors":"Zhao Donglu,&nbsp;Song Yuqin,&nbsp;Qin Jiayue,&nbsp;Tong Hongyan,&nbsp;Ding Kaiyang,&nbsp;Cai Qingqing,&nbsp;Huang Huiqiang,&nbsp;Wu Lili,&nbsp;Jing Hongmei,&nbsp;Zhang Liling,&nbsp;Qian Wenbin,&nbsp;Bai Ou,&nbsp;Cao Shanbo,&nbsp;Jin Jie,&nbsp;Zhu Jun,&nbsp;Ma Jun","doi":"10.1002/ajh.70357","DOIUrl":"10.1002/ajh.70357","url":null,"abstract":"&lt;p&gt;Peripheral T-cell lymphoma (PTCL) represents a diverse and aggressive category of hematologic malignancies that significantly affects patient outcome [&lt;span&gt;1&lt;/span&gt;]. PTCL is characterized by multiple subtypes, including NK/T-cell lymphoma (NKTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), and PTCL, not otherwise specified (PTCL-NOS), and is associated with considerable morbidity and mortality, primarily due to poor response to conventional therapies [&lt;span&gt;2-4&lt;/span&gt;]. Recent advancements in molecular diagnostics have highlighted circulating tumor DNA (ctDNA) as a valuable biomarker for various cancers, providing real-time insights into tumor dynamics and treatment responses [&lt;span&gt;5-7&lt;/span&gt;]. Previous studies have established the role of ctDNA in assessing tumor burden, prognostication, and monitoring treatment efficacy across several hematological malignancies [&lt;span&gt;8-10&lt;/span&gt;]. Moreover, identifying specific ctDNA alterations associated with treatment response may enhance prognostic evaluation and support therapeutic decision-making [&lt;span&gt;11, 12&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Despite its promising potential, significant gaps remain regarding the clinical applicability of ctDNA in PTCL. In particular, comprehensive and prospective studies examining the association between ctDNA dynamics and treatment outcomes across different PTCL subtypes are lacking. To address these gaps, we conducted a prospective, multicenter, observational cohort design using next-generation sequencing (NGS) to analyze tumor DNA (tDNA) and plasma-derived ctDNA mutation profiles and to evaluate the prognostic significance of ctDNA dynamics in 104 patients with PTCL (Tables S1–S3). The study was approved by the Ethics Committee at the participating centers in accordance with the Declaration of Helsinki.&lt;/p&gt;&lt;p&gt;Figure 1A,B illustrate the study design flowchart. Thirty-three patients provided baseline, post-four-cycle, and end-staging ctDNA samples, along with paired baseline tDNA samples for concordance, dynamic monitoring, and prognostic analyses. Thirty patients provided baseline and post-four-cycle ctDNA samples with paired baseline tDNA for concordance and dynamic monitoring analysis. Three patients provided baseline and end-staging ctDNA samples with paired baseline tDNA for concordance, dynamic monitoring analysis, and prognostic analyses. Thirty-eight patients contributed baseline tDNA and paired ctDNA samples for concordance analysis only (Figure 1B).&lt;/p&gt;&lt;p&gt;Baseline tDNA detection identified 161 mutated genes, comprising 529 mutation events. The most frequently mutated genes were &lt;i&gt;TET2&lt;/i&gt; (51.0%), followed by &lt;i&gt;RHOA&lt;/i&gt; (34.6%), &lt;i&gt;DNMT3A&lt;/i&gt; (24.0%), and both &lt;i&gt;STAT3&lt;/i&gt; and &lt;i&gt;TP53&lt;/i&gt; (13.5%) (Figure 1C), similar to the spectrum of ctDNA mutations (Figure 1D). The percentage of cases detectable via ctDNA in each subtype of PTCL is shown in Table S4.&lt;/p&gt;&lt;p&gt;Among the 398 concordant mutations detected in both tDNA and ctDNA (Figur","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 S3","pages":"65-71"},"PeriodicalIF":9.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Treatment Landscape and Advances in Lymphoma in China: A Special Issue","authors":"Yuqin Song","doi":"10.1002/ajh.70471","DOIUrl":"10.1002/ajh.70471","url":null,"abstract":"&lt;p&gt;Lymphoma is a significant and growing health burden in China, with an estimated annual incidence of approximately 6.03 per 100 000 people and an increasing trend over the past 20 years [&lt;span&gt;1&lt;/span&gt;]. The high population and rapid economic development of China have created challenges and opportunities for research on lymphoma and clinical care. Over the past decade, there has been considerable progress in research on understanding the biology, improving diagnostic precision, and developing novel therapeutic strategies for lymphoid malignancies in China. From the widespread adoption of immunochemotherapies and targeted agents to the expansion of hematopoietic stem cell transplantation and Chimeric Antigen Receptor T-cell therapy (CAR-T), management of lymphoma in China has transformed. Despite these advances, significant discrepancies remain in access to high-quality medical care, and the unique genetic and epidemiological features of Chinese patients warrant further investigation.&lt;/p&gt;&lt;p&gt;In this special issue of the &lt;i&gt;American Journal of Hematology&lt;/i&gt;, we present nine outstanding manuscripts that collectively illuminate the current treatment landscape and future directions for lymphomas in China. These articles, authored by leading experts from major academic centers across the country, cover a broad spectrum of disease subtypes, including peripheral T-cell lymphoma (PTCL), extra-nodal natural killer/T-cell lymphoma (NKTCL), primary central nervous system lymphoma (PCNSL), diffuse large B-cell lymphoma, and Hodgkin lymphoma, and address critical topics, including circulating tumor DNA (ctDNA) monitoring, novel targeted and immunotherapeutic approaches, and transplantation strategies. Collectively, they provide a comprehensive snapshot of the advanced Chinese lymphoma research and clinical practice, highlighting the unique challenges and opportunities that lie ahead.&lt;/p&gt;&lt;p&gt;Peripheral T-cell lymphomas are a heterogeneous group of aggressive malignancies with historically poor outcomes, and several studies have addressed this unmet need from a complementary angle. Zhao et al. [&lt;span&gt;2&lt;/span&gt;] reported the first prospective multi-center observational study of Chinese patients with PTCL, demonstrating the utility of ctDNA for mutation profiling, efficacy monitoring, and prognostic evaluation [&lt;span&gt;2&lt;/span&gt;]. With a sensitivity of 75.2% for concordant mutations between ctDNA and tumor tissue DNA, this study validated the feasibility of liquid biopsy in this setting and revealed that dynamic changes in ctDNA concentration and variant allele frequency were closely correlated with treatment response and progression-free survival. Notably, the sensitivity of ctDNA varied by subtype, with the highest sensitivity in angioimmunoblastic T-cell lymphoma (AITL) (82.1%) and the lowest in NKTCL (37.1%), highlighting the need for subtype-specific considerations. Similarly, Li et al. [&lt;span&gt;3&lt;/span&gt;] presented the RCLARITY trial, a prospective Phase II study ","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 S3","pages":"3-5"},"PeriodicalIF":9.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70471","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148729137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}